Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CCR8 | P51685 | 3/20 | 0.39 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10003901 | 0.92 | SMO (0.44) | SMOMEN1POLBKMT2ACCR8 | |
| SCHEMBL10003822 | 0.92 | SMO (0.42) | SMO | |
| SCHEMBL10003397 | 0.90 | SMO (0.41) | SMONPSR1MEN1KMT2A | |
| SCHEMBL10003469 | 0.87 | SMO (0.64) | SMONPSR1MEN1POLBKMT2A | |
| SCHEMBL10003576 | 0.87 | SMO (0.46) | SMONPSR1BRPF1MEN1POLB | |
| SCHEMBL10003899 | 0.85 | SMO (0.48) | SMONPSR1BRPF1MEN1POLB | |
| SCHEMBL10003104 | 0.85 | SMO (0.43) | SMONPSR1BRPF1MEN1KMT2A | |
| SCHEMBL12824597 | 0.84 | NPSR1 (0.42) | SMONPSR1MEN1POLBKMT2A | |
| SCHEMBL10004341 | 0.83 | NPSR1 (0.41) | SMONPSR1MEN1POLBKMT2A | |
| SCHEMBL10003879 | 0.81 | BRPF1 (0.51) | BRPF1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2471789-B9 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-03-25 | — | — | EP | disclosed |
| EP-2471789-B1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-09-17 | — | — | EP | disclosed |
| US-8486965-B2 | Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-16 | — | — | US | disclosed |
| US-8486965-B2 | Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-16 | — | — | US | disclosed |
| US-8486965-B2 | Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-16 | — | — | US | disclosed |
| US-20120220569-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20120220569-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| EP-2471789-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-07-04 | — | — | EP | disclosed |
| EP-2471789-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220569-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | SMO, GLI1, SHH | SMO 1/4885NPSR1 2438/4885BRPF1 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.